Dysregulated phosphatidylglycerol metabolism in dorsal root ganglia contributes to pain hypersensitivity in a mouse model of Fabry disease.

Authors

Nan Lian, Jinfeng Luo, Wei Ou, Junyan Wang, Jiayi Du, Zhimin Tan, Xinrong Zuo, Yan Yin, Cheng Zhou, Tao Li, Su Lui, Peilin Lu

Published in

Neurobiology of disease. Pages 107595. Sep 04, 2026. Epub Sep 04, 2026.

Abstract

Fabry disease (FD) is a genetic disorder caused by a deficiency of alpha-galactosidase A. Neuropathic pain is a hallmark of FD, beginning in early childhood and persisting throughout life. Current therapies for FD, such as enzyme replacement therapy and oral chaperone therapy, have limited impact on alleviating pain symptoms. Therefore, there is an urgent need to elucidate the precise molecular and metabolic mechanisms underlying FD-related pain to identify new therapeutic targets. In this study, we found that 8-week-old Fabry mice exhibited pronounced pain hypersensitivity, with no sex differences. Then, bilateral L4-L6 dorsal root ganglia (DRGs) were harvested from Fabry and wild-type (WT) mice of both sexes to dissect the molecular basis of pain. Transcriptomic profiling revealed distinct alterations in lipid metabolism-related genes within Fabry DRGs. Subsequent targeted lipidomic analysis identified robust accumulation of phosphatidylglycerol (PG), particularly elevated levels of PG (18:1/22:6) and PG (18:2/22:6) in Fabry DRGs. PG-associated synthase PGS1 was upregulated, while the PG hydrolytic activity of sPLA2s was inhibited. Following PGS1 knockdown or sPLA2s activity restoration, PG accumulation and pain hypersensitivity in Fabry mice were mitigated. Given the mitochondrial localization of PGS1, we observed profound mitochondrial disruption in Fabry DRGs, where aberrant PG metabolism contributes to this dysfunction. Thus, our study provides new insights into DRG pathogenesis in FD and uncovers dysregulated PG metabolism as a promising therapeutic target for alleviating Fabry pain.

PMID:
42697517
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.